Why the study?
Does VTE prophylaxis with low-molecular-weight heparin or unfractionated heparin reduce 30-day VTE-attributable mortality and healthcare costs in acutely ill medical inpatients compared to no prophylaxis?
Does VTE prophylaxis with low-molecular-weight heparin or unfractionated heparin reduce 30-day VTE-attributable mortality and healthcare costs in acutely ill medical inpatients compared to no prophylaxis?
Implementing ACCP-recommended VTE prophylaxis with LMWH or UFH in acutely ill medical inpatients reduces VTE-attributable deaths and provides net cost savings to the healthcare system.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2015) studied Acutely ill medical inpatients at risk for venous thromboembolism (n=10,000). Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) vs. No prophylaxis was evaluated on Deaths within 30 days of admission attributable to VTE (ARR 0.47%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: